StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Biogen (BIIB) Plans to Spinoff Hemophilia Business into Independent, Publicly-Traded Company
May 3, 2016 7:31 AM
Biogen Inc. (NASDAQ: BIIB) announced that it intends to spin off its hemophilia business as an independent, publicly traded company ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
Hot Corp. News
Hot IPOs
IPOs
Management Comments
Spinoffs
Next Articles
Leerink Modestly Positive on Biogen's (BIIB) Hemophilia Spin; Remains Cautious on Rest of Company
May 3, 2016 2:52 PM
Form 8-K BIOGEN INC. For: May 03
May 3, 2016 7:32 AM
Biogen Announces Intent to Spin off Its Hemophilia Business
May 3, 2016 7:30 AM
Form 4 BIOGEN INC. For: May 01 Filed by: COVINO GREGORY F
May 2, 2016 4:40 PM
Alder BioPharma (ALDR) is Janus Capital's Top M&A Biotech Pick - Bloomberg
May 2, 2016 3:40 PM
Form 8-K BIOGEN INC. For: Apr 29
April 29, 2016 11:07 AM
Biogen (BIIB), AbbVie (ABBV) Receive Positive CHMP Opinion on ZINBRYTA in MS
April 29, 2016 7:39 AM
Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment of Multiple Sclerosis
April 29, 2016 7:39 AM